Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether-lumefantrine plus atovaquone-proguanil tri-therapy for uncomplicated malaria in Gabon
ISRCTN61526229Phase 2Completed
- Sponsor
- Kwame Nkrumah University of Science and Technology
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of artemether, lumefantrine, atovaquone and proguanil in malaria and Malaria (2 arms), sponsored by Kwame Nkrumah University of Science and Technology. Primary endpoint: Frequency and severity of adverse events. Started Sep 2020; status: completed.
02
Drugs
artemetherlumefantrineatovaquoneproguanil
03
Conditions
malariaMalaria
Beyond the preview
Go deeper on ISRCTN61526229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN61526229.